StockData
Camp4 Therapeutics Corp logo

Camp4 Therapeutics Corp (CAMP) stock

CAMPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$4.10+0.10 (+2.50%)

Close on Nov 18, 2026Market cap $257.29MP/E –Yield 0.00%

Camp4 Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Camp4 Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$28.72M. For fiscal 2025 it was -$29.83M.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$29.83M–
FY2024Dec 31, 2024-$46.00M–
FY2023Dec 31, 2023-$44.83M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$12.82M–
Q1 FY2026Mar 31, 2026-$10.98M–
Q4 FY2025Dec 31, 2025$6.29M–
Q3 FY2025Sep 30, 2025-$11.22M–
Q2 FY2025Jun 30, 2025-$10.34M–
Q1 FY2025Mar 31, 2025-$14.57M–
Q4 FY2024Dec 31, 2024-$11.55M–
Q3 FY2024Sep 30, 2024-$9.69M–
Q2 FY2024Jun 30, 2024-$13.60M–
Q1 FY2024Mar 31, 2024-$11.16M–
Q4 FY2023Dec 31, 2023-$12.03M–

More Camp4 Therapeutics figures

See a number that looks wrong?